Resistance Exercise and Cannabis Use
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03867786|
Recruitment Status : Not yet recruiting
First Posted : March 8, 2019
Last Update Posted : January 20, 2023
|Condition or disease||Intervention/treatment||Phase|
|Cannabis Use Disorder||Behavioral: Exercise Behavioral: Video Control||Not Applicable|
Cannabis is the most widely used illicit drug and rates of hazardous use, and cannabis use disorders (CUDs), have continued to rise in recent years. The highest rates of use and CUDs are seen in young adults (20 - 24 years old) with more than 50% of young adults reporting lifetime use of cannabis, 35% report use in the past year, and 20% report use in the past month. Increased exposure produces higher risk for detrimental psychological and behavioral effects of cannabis use. Given this increased prevalence of cannabis use and associated risks, identifying effective behavioral strategies that reduce cannabis craving, negative psychological effects, and alter neurobiological mechanisms underlying problematic cannabis use are an avenue of needed research. Exercise, particularly resistance exercise, is a behavioral intervention with considerable potential as an adjunctive treatment for CUD.
The aims of this proposal seek to address these issues by implementing acute resistance exercise protocol in men and women who have cannabis use disorder. This proposal will: 1 examine the effect of an acute resistance exercise protocol on affect, stress, and compulsive urge to use in non-treatment seeking young adults with CUD 2.examine whether an acute resistance exercise session in individuals with CUD is associated with induced alterations in the appetitive/ reward hormone ghrelin These findings will inform the further development for exercise interventions for cannabis use disorder that can be used with the aim of supporting individuals with CUD reduce use and decrease the negative effects of withdrawal.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Acute Effects of Resistance Exercise on Cannabis Use and Craving|
|Estimated Study Start Date :||February 1, 2023|
|Estimated Primary Completion Date :||August 31, 2023|
|Estimated Study Completion Date :||December 1, 2024|
Experimental: Exercise Condition
Participants will undergo a 40 minute exercise protocol
Participants will complete an acute exercise visit.
Active Comparator: Video Control Condition
Participants will view a 40 minute nature video
Behavioral: Video Control
Participants will complete a video control visit.
- Cannabis Craving [ Time Frame: change from baseline ]Craving Marijuana Craving Questionnaire (MCQ) The 45-item MCQ is a multi-dimensional questionnaire that assesses marijuana craving. It is based on the the Cocaine Craving Questionnaire and uses items that touch on four specific constructs characterizing craving for marijuana: (1) compulsivity, an inability to control marijuana use; (2) emotionality, use of marijuana in anticipation of relief from withdrawal or negative mood; (3) expectancy, anticipation of positive outcomes from smoking marijuana; and (4) purposefulness, intention and planning to use marijuana for positive outcomes. Each item is rated on a seven-point Likert-type scale ranging from "strongly agree to strongly disagree"
- Cannabis Craving [ Time Frame: Change from baseline ]Total Ghrelin as measured by 0.5mL plasma
- Cannibis Consumption [ Time Frame: change from Baseline ]endocannabinoid N-arachidonoylethanolamine (AEA)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03867786
|Contact: Gwendolyn Thomas, PhDemail@example.com|